NCT00868114

Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer

A Phase II Study of Apoptosis Induction Through Direct Tumor Injection of TNFerade(TM)or Radiation Alone Followed by KLH-Pulsed Autologous Dendritic Cells in Patients With Unresectable Pancreatic Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Leo W. Jenkins Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study uses radiation or a gene therapy agent, TNFerade in addition to a dendritic cell vaccine in patients with locally advanced or low volume metastatic pancreatic cancer. The use of TNFerade or radiation serves to generate cell death stimulating the immune response. The dendritic cell vaccine may direct a distant and lasting effective anti-tumor immune response to achieve a local and systemic clinical benefit.

Conditions

• Metastatic Pancreatic Cancer

Interventions

Type	Name	Description
BIOLOGICAL	KLH-pulsed autologous dendritic cell vaccine	5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks

Timeline

• Start date: 2006-07-01
• Primary completion: 2013-07-01
• Completion: 2015-12-01
• First posted: 2009-03-24
• Last updated: 2018-10-17

Locations

1 site across 1 country: United States